News

Administration of autologous HER2-specific CAR-modified virus specific T Cells was safe and had clinical benefit for some patients with progressive glioblastoma, a disease with limited effective therapeutic options.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

Sophie Papa, MD, discusses the early-phase results and the logic behind studying CAR T-cell therapy in solid tumors, such as head and neck cancer.

The FDA has granted a breakthrough therapy designation to tisagenlecleucel-T (CTL019) for use as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma after the failure of at least 2 prior therapies.

Using state-of-the-art gene editing technology, researchers have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT), a highly aggressive and therapy-resistant brain tumor.

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.

Frederick L. Locke, MD, discusses the ZUMA-1 trial in non-Hodgkin lymphoma and the next steps going forward.

Axitinib was a promising newcomer in the renal cell carcinoma field when it was introduced as a second-line therapy 5 years ago. Now it is being displaced by newer therapies, a development that may serve as a harbinger for the evolution of treatment patterns in other tumor types with a bounty of novel agents.

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with squamous cell cancer of the head and neck following progression on platinum-based therapy.

Michel Sadelain, MD, PhD, discusses CRISPR and its effect on CAR T cells.

Stephan Grupp, MD, PhD, discusses the phase II ELIANA study results and the next steps with chimeric antigen receptor T-cell therapy in acute lymphoblastic leukemia.

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.

Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.

How will drug developers price gene therapy treatments to recover their investment and ensure that society can bear the impending cost?

The company did not recover from the 5 patient deaths associated with JCAR015 in 2016.

The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.

Chimeric antigen receptor T-cell therapies have already produced clinical trial results that, even by the lofty standards set by emerging immunotherapies, have been stunning.

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.

Evidence is mounting that stem cell transplants help in MS.

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

The European Commission has expanded the indication for lenalidomide (Revlimid) to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.

The FDA has approved lenalidomide as maintenance therapy in patients with multiple myeloma following autologous stem cell transplant.